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 The main causes of community-acquired bacterial 
meningitis (CABM) in immunocompetent patients 
are Streptococcus pneumoniae, Neisseria meningitidis, 
Haemophilus influenzae and, less commonly, Listeria 
monocytogenes. In immunocompromised patients, 
specifically those with HIV/AIDS, S. pneumoniae remains the most 
frequently isolated organism.[1,2] 
Ceftriaxone is currently recommended as first-line therapy in 
South Africa (SA) if the aetiology is unknown, because adequate 
concentrations in the cerebrospinal fluid (CSF) are achieved and it is 
effective against the organisms described above (with the exception of 
L. monocytogenes).[3,4] According to the Clinical Laboratory Standards 
Institute, S. pneumoniae is sensitive to ceftriaxone if the minimum 
inhibitory concentration (MIC) is ≤1 µg/ml, it has intermediate 
resistance if MIC is 2 µg/ml and high-level resistance if the MIC is 
≥4  µg/ml. This would imply that for efficacy the levels in the CSF 
should exceed 1 µg/ml, and preferably 2 µg/ml, for at least 50%, but 
preferably 100% of the treatment time.[5,6] 
The original formulation is Rocephin (ROC) (Hoffman-La Roche, 
Basel Switzerland). One of the many generic preparations is Aspen 
Ceftriaxone (AC). Registration of generic antibiotics with the SA 
Medicines Control Council (MCC) requires proof of equivalence 
with regard to active pharmaceutical ingredient. This internationally 
accepted standard does not require clinical studies to show efficacy 
or activity at the target site.[4] Consequently, there are very few studies 
that compare the pharmacokinetics (PK) of original preparations 
with generics. Those that are available have shown that some generics 
in some instances may have significantly inferior activity.[7-10] This, 
and the prevalent belief in SA that generic antibiotics are inferior, 
prompted our study. 
Objectives
• Primary: To compare parenteral AC and ROC concentrations 
administered as 2 g 12-hourly in plasma/CSF of adults with CABM.
• Secondary: To evaluate the safety of AC through adverse event 
reporting, and clinical/laboratory data from visit 2 to visit 5.
Methods
This randomised, double-blind, parallel group study utilised a non-
inferiority design and was conducted at three centres – two in SA and 
one in Rwanda – from May 2010 to September 2011. The protocol was 
approved by the University of the Witwatersrand Human Research 
Ethics Committee, as well as the MCC (trial ref. no. 20090906). All 
patients or their representatives gave informed consent. 
Male and female patients ≥18 years of age were eligible if they had 
confirmed CABM. Patients were excluded if: (i) they had received 
ceftriaxone <48  hours before admission; (ii) a second antibiotic 
(except vancomycin) was anticipated to be required; (iii) there was 
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Background. Community-acquired bacterial meningitis (CABM) is a life-threatening condition that is common among immunocompromised 
individuals. Intravenous ceftriaxone, of which Rocephin (ROC) is the originator brand, is recommended as first-line therapy in South 
Africa. Despite concerns regarding therapeutic equivalence with generic agents, this is the first study that has been conducted comparing 
clinical pharmacokinetics (PK) of a generic ceftriaxone formulation with the originator. 
Objective. To compare the PK and safety of Aspen Ceftriaxone (AC) and ROC in the treatment of adult CABM. 
Methods. A total of 63 eligible patients were randomised 1:1 to receive 2 g of either medication twice daily for a duration based on the 
identity of the causative organism and their physician’s clinical judgment. The primary endpoint of this study was the comparison of clinical 
PK, specifically the concentrations of each drug in the cerebrospinal fluid with corresponding paired plasma samples. While this study was 
underpowered to assess efficacy, safety could be evaluated on the basis of reported adverse events. 
Results. The two patient groups were epidemiologically similar. There were no statistically significant differences in PK between either agent, 
nor any difference with regard to safety.
Conclusion. AC can be considered as equivalent to ROC with regard to PK and safety in patients with CABM. 
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hypersensitivity to β-lactam antibiotics; 
(iv)  there was any concurrent systemic 
disease, other than HIV/AIDS; (v) there 
was severe renal impairment (creatinine 
clearance <30 ml/min); (vi) the pathogen 
was resistant to ceftriaxone; (vii) foreign 
bodies or anatomical defects that predisposed 
patients to meningitis were present; (viii) the 
meningitis was mycobacterial, viral, fungal 
or parasitic; or (ix) the patient was pregnant.
A lumbar puncture was performed to 
obtain CSF for microscopy, cell count, 
glucose, protein, bacterial antigens, culture 
and antibiotic susceptibility; simultaneously, 
a blood glucose level was obtained. The dose 
of 2 g 12-hourly was selected in accordance 
with standard SA treatment guidelines and 
eligible patients were randomised 1:1 to receive 
either medication. The duration of treatment 
was dependent on the aetiological organism 
and clinical judgement of the investigator, 
and was either 7 - 10 or 10 - 14 days. The 
use of concomitant vancomycin was left 
to the investigator’s discretion. The study 
consisted of 5 visits: visit 1 (screening), visit 2 
(randomisation), visit 3 (on treatment: days 2; 
7 - 10 or 10 - 14), visit 4 (end of treatment: days 
10 - 14) and visit 5 (follow-up: days 42 - 49). 
Physicians and subjects were blinded 
as to which treatment was administered. 
Non-inferiority was concluded if the lower 
limit of the 95% confidence interval of the 
treatment difference in PK profile, and safety 
showed no statistical difference. 
Disease severity was assessed using the 
Acute Physiology and Chronic Health 
Evaluation (APACHE) II score. 
PK assessment
This was achieved by comparing concen-
trations of each drug in the CSF 1 to 2 
hours after the fifth dose (visit 3, day 3), 
with corresponding plasma samples. A liquid 
chromatography-tandem mass spectrometry 
(LC-MS/MS) assay was developed and vali-
dated for the determination of ceftriaxone 
concentrations in CSF over the range of 0.125 
- 4.00 μg/ml, and in human plasma over the 
range of 0.5 - 500 µg/ml. 
Due to the unavailability of human CSF 
in quantities required for the preparation of 
calibration standards and quality controls used 
for the validation of bioanalytical methods, 
artificial CSF was prepared. Heparinised 
plasma was utilised for a similar purpose in the 
plasma method. The assay methods entailed 
precipitation of proteins to release ceftriaxone 
into the supernatant. The supernatant was 
acidified with 0.1% formic acid, and samples 
analysed by liquid chromatographic separation 
using a Phenomenex Onyx C18 100 × 3.0 mm 
analytical column. An isocratic mobile phase 
consisting of 0.2% trifluoroacetic acid and 
acetonitrile (50:50 v/v) was used at a flow 
rate of 1 000 µl/min. The retention time 
for ceftriaxone was ~0.56 min. An Applied 
Biosystems API 4 000 mass spectrometer 
at unit resolution in the multiple reaction 
monitoring (MRM) mode was used to monitor 
transition of the deprotonated precursor ions 
m/z 555 to the product ions m/z 396 for 
ceftriaxone. Electrospray ionisation (ESI) was 
used for ion production. 
Accuracy and precision were assessed 
over three consecutive, independent runs, 
with the assay compared with standards and 
quality control samples prepared for each 
of the matrices (i.e. CSF and plasma). In 
the validation, stability of the analyte was 
assessed at room temperature, during four 
freeze-thaw cycles and also during long-
term storage at -70°C. 
Safety assessment 
Spontaneously reported adverse events, 
physical examination and clinical and 
laboratory data were collected at each visit. 
Statistical tests
Continuous variables were summarised 
by sample size, mean ± standard deviation 
(SD) and minimum and maximum values. 
Categorical variables were summarised 
by frequency counts/percentages. Paired 
and two-sample t-tests and Fisher’s exact 
tests were used to test for the significance 
of changes in values and parameters as 
appropriate. 
Statistical analysis was performed by 
ClinStat CC, Pretoria, SA. All analyses were 
carried out using SAS version 9.2. Analysis 
and interpretation of the data were strictly 
objective and in accordance with ethical 
statistical practice. 
Results
A total of 63 patients (57 from SA and 6 
from Rwanda) were randomised. Thirty-one 
received AC and 32 ROC. All were included 
in the PK and safety populations. Analysis 
of the population is shown in the consort 
diagram in Fig. 1. Demographic profiles are 
shown in Table 1. 
Clinical characteristics 
The baseline vital signs of the two groups were 
similar. Table 2 shows the APACHE II scores 
within the first 24 hours post admission. 
Certain parameters for the APACHE II 
scores were assumed. The PaO2 was taken 
to be normal since no patient had comorbid 
respiratory disease or required mechanical 
ventilation. For chronic health points, all 
subjects received a score of 5. 
Mean±SD blood glucose values were 
5.88±2.21 mmol/l and 6.05±1.63 mmol/l 
and mean±SD CSF levels were 2.01 
±1.83  mmol/l and 2.81±3.43 mmol/l at 
screening for AC and ROC, respectively. 
Blood cultures were performed on 15 
patients in each group; 6 (40%) of the AC 
patients were positive v. 4 (26.7%) in the 
ROC group. 
Visit 1: Screening, baseline
Ceftriaxone: N=31
Rocephin: N=32
Visit 2: Start of treatment and 
randomisation
Ceftriaxone: N=31
Rocephin: N=32
Visit 3, day 2: On treatment
Ceftriaxone: N=31
Rocephin: N=29
Visit 3, day 3: On treatment
Ceftriaxone: N=31
Rocephin: N=28
Visit 3, day 4: On treatment
Ceftriaxone: N=30
Rocephin: N=24
Visit 3, day 5: On treatment
Ceftriaxone: N=30
Rocephin: N=23
Visit 3, day 6: On treatment
Ceftriaxone: N=28
Rocephin: N=21
Visit 5: Follow-up
Ceftriaxone: N=20
Rocephin: N=14
Fig. 1. Consort flow diagram.
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Laboratory confirmation of CABM remains a challenge due to the 
fastidious nature of many of the organisms; as a result negative 
cultures are common. In 34 patients there was neither bacterial 
growth nor evidence of bacterial presence on the final analysis. In 6 
patients there was an indication of a bacterial aetiology of meningitis, 
with a positive Gram stain or neutrophil predominance, but no 
confirmation on culture. Cultures were positive in 12 patients, of 
which 9 were S. pneumonia and 3 N. meningitides. One patient grew 
an Enterobacter cloacae (which is uncommon, but may reflect the 
immune-suppressed population in this study). Dual infection with 
Cryptococcus and Mycobacterium tuberculosis (MTB) occurred in 1 
patient each. Cryptococcus (in 3 patients) and MTB (in 1 patient) 
were cultured as a single organism causing meningitis.
Validation of the assay method
Validation in artificial CSF was robust, with an accuracy of -0.3 - 2.5% 
over the range of 0.125 - 4.00 µg/ml, and a precision of 4.4 - 13.5% (based 
on performance of the quality control samples). Similarly, the accuracy 
was 2.7 - 7.0% over 0.5 - 500 µg/ ml, and precision -5.2 - 2.0% in plasma.
Ceftriaxone, reported to be stable for up to 52 and 57 days when stored 
at -70°C, was stable in CSF and plasma for 4 and 15 hours, respectively, at 
room temperature and when subjected to four freeze-thaw cycles. 
Endogenous components of plasma had an insignificant effect 
on reproducibility of the method when human plasma originating 
from 10 different sources was analysed; the assay was unaffected by 
haemolysed blood (1%) in plasma.
The assay met the currently accepted validation standards for 
analytical methods with regard to bioavailability, bioequivalence 
and PK studies as outlined by the United States Food and Drug 
Administration (FDA)[11] and the report from the conference on 
Quantitative Bioanalytical Methods, Validation and Implementation. [12] 
As the assay method for the CSF was validated on artificial CSF, some 
assessments were omitted that would otherwise have been performed 
had human CSF been available in adequate quantities.
Analytical results
CSF and plasma levels of both drugs, compared in Table 3, did not 
differ significantly (p=0.182 for plasma and p=0.179 for CSF, Fisher’s 
exact test). As shown in Tables 4 and 5, the Wilcoxon rank test was 
used to compare medians because the numbers were small and 
comparison of means by the t-test was unreliable. The medians varied 
significantly in plasma (p=0.028) but not in CSF (p=0.881). The 
statistical comparisons did not show significant differences.
Safety evaluation/assessment
Of the 63 subjects, 16 in the ROC and 9 in the AC group experienced 
serious adverse events. All 16 patients in the ROC group died. 
Death was not believed to have a causal relationship to the study 
drug: 9 deaths were due to concurrent illness, 4 to cerebral lesions 
complicating meningitis and in 3, cause of death was unknown. 
Table 2. APACHE II scores
Aspen Ceftriaxone* Rocephin*
Total, N 31 32
Mean±SD 13.2±3.6 13.3±5.4
Median 13 12.5
Min/max 8/21 7/27
APACHE = Acute Physiology and Chronic Health Evaluation; SD = standard deviation.
*p-value Aspen Ceftriaxone v. Rocephin was not significant.
Table 1. Demographic characteristics of subjects
 
Aspen Ceftriaxone 
(N=31)
Rocephin 
(N=32)
Age (years), mean±SD 36.8±34 38.6±36 
Height (cm), mean±SD 164.9±11.7 163.3±11.5 
Weight (kg), mean±SD 60±13.6 58.8±12.3
Gender (female), n 15 18
Child-bearing age 14 13
Males, n 16 14
SD = standard deviation 
Table 4. Statistics for plasma levels of Aspen Ceftriaxone and 
Rocephin (excluding BQLs)
Aspen Ceftriaxone Rocephin
Total, N 20 13
Mean±SD 122.46±83.57 176.12±61.94
Median 110 184
IQR 56.35 - 156 174 - 223
Min/max 22.6/317 44.5/234
BQLs = below quantifiable levels; SD = standard deviation; IQR = interquartile range.
Table 3. Comparison of plasma/CSF levels of 
Aspen Ceftriaxone and Rocephin in patients
Sample/quantity 
Patients, n (%) 
Aspen Ceftriaxone Rocephin 
Plasma (µg/ml) 22 (100) 17 (100)
>200 3 (13.64) 5 (29.41)
>100 - 200 9 (40.91) 6 (35.3)
≤100 8 (36.36) 2 (11.76)
BQL 2 (9.09) 4 (23.53)
CSF (µg/ml) 24 (100) 18 (100)
>4 11 (45.83) 9 (50)
>2 - 4 9 (37.5) 3 (16.67)
>1 - 2 1 (4.17) 0 (0)
≤1 0 (0) 2 (11.11)
BQL 3 (12.5) 4 (22.22)
CSF = cerebrospinal fluid; BQL = below quantifiable level. 
Table 5. Statistics for CSF levels of Aspen Ceftriaxone and 
Rocephin (excluding BQLs)
Aspen Ceftriaxone Rocephin
Total, N 21 14
Mean±SD 3.50±0.78 3.26±1.2
Median 4 4
IQR 3.23 - 4 2.75 - 4
Min/max 1.47/4 0.57/4
CSF = cerebrospinal fluid; BQLs = below quantifiable levels; SD = standard deviation; 
IQR = interquartile range.
RESEARCH
909  December 2013, Vol. 103, No. 12  SAMJ
In the AC group, there were 7 deaths. Similarly, no death was 
believed to have a causal relationship to the drug. In 6 patients, 
death was due to concurrent illness and in 1 due to cerebral lesions 
complicating meningitis; in 2 there was a probable causal relationship 
to concomitant medication. One patient suffered a life-threatening 
event (worsening of meningitis); 1 had a prolonged hospital stay. 
Only 1 patient in the AC group received vancomycin.
Outcomes 
Of the 31 patients who received AC, 29 completed treatment; 21 
recovered fully and were discharged, 7 died and 1 was referred for 
surgery, remaining in hospital for a craniotomy for evacuation of a 
haematoma before visit 5 (follow-up). 
In the ROC group, 24 patients completed the treatment; 16 
recovered fully and were discharged, and 8 died. 
In the AC group, 22 patients completed the study; of the 9 that did 
not, 7 died in hospital, 1 died after discharge and one patient was lost 
to follow-up. In the ROC group, 15 patients completed the study; 16 
did not due to adverse events and 1 was lost to follow-up.
Discussion
This study evaluated the PK profiles of ROC and AC. Although there 
was a significant difference in survival between the two groups, numbers 
were insufficient to eliminate confounding factors such as HIV positivity, 
degree of immunosuppression, use of antiretrovirals, co-existent disease 
and delay before presentation. The primary endpoint was, however, 
achieved in that CSF/plasma levels of the drugs were equivalent and AC 
was found to be non-inferior to ROC. Additionally, AC had a similar 
safety profile to ROC. Although there were more fatalities in the cohort 
receiving the latter, in none was there a causal relationship to the drug. 
The ability of an antimicrobial agent to eradicate pathogens is often 
predicted by its pharmacodynamic and PK properties. In meningitis 
the ability of the agent to penetrate the blood-brain barrier and achieve 
rapid and sustained bactericidal concentrations is the best predictor of 
bacterial killing. Penetration of the blood-brain barrier is dependent on 
protein binding, lipophilicity, molecular weight, efflux transporters and 
the degree of inflammation of the meninges. [13,14] Ceftriaxone has adequate 
penetration and is not affected by efflux transporter systems, making it 
suitable for central nervous system infections, including meningitis. [15] 
A recent study in children showed that a β-lactam infusion along with 
paracetamol lowered mortality in childhood bacterial meningitis in the 
first 3 days, but overall mortality was unchanged.[16] This improvement 
was thought to be related to the prolonged infusion of the antibiotic, 
rather than the adjuvant paracetamol, because the antibiotics exhibit 
time-dependent killing and infusion increases the time above the 
MIC.[17] All of our patients had confirmed meningitis, with evidence of 
inflammation, but there was a poor correlation between plasma and 
CSF levels as measured after the fifth dose. In the AC group, 21/24 and 
12/18 in the ROC group had CSF levels >1 μg/ml (Table 3). Of particular 
concern, however, was that significant numbers in both groups had 
CSF levels below the quantifiable range: 3 (12.5%) and 4 (22.2%) in 
the AC and ROC groups, respectively. This was despite documented 
administration of the drug. An additional 2 patients in the ROC group 
had CSF levels <1  μg/ml, which was likely also to be subtherapeutic. 
Thus, there were 9 patients with potentially subtherapeutic CSF levels. 
These low CSF levels may have been due to errors in the estimation 
method (despite being performed by means of a validated technique), 
or due to undocumented administration or transport errors. These 
are all unlikely, as doses were observed and ampoules collected after 
each treatment day. It is also possible that augmented renal clearance 
may have contributed to low levels. This phenomenon has been well 
described in septic patients and results from an increase in glomerular 
filtration due to factors such as the increased cardiac output that 
occurs in early sepsis and the use of catecholamine inotropes.[18,19] 
Another factor that may have contributed to lower levels is serum 
albumin,[20,21] which, when low, increases the free fraction and in turn 
increases the volume of distribution and excretion of highly protein-
bound drugs. We were not, however, able to relate the low drug 
levels to albumin in these patients. We did not measure glomerular 
filtration rate (GFR) and the calculated creatinine clearance, as a 
measure of GFR, was inaccurate in this setting.
Approximately 20 - 60% of pneumococci in SA have an MIC of 
2  μg/ml for penicillin, but there is little resistance to third-generation 
cephalosporins in either the private or public sectors, with most MICs 
at ≤0.5 μg/ml.[4] This suggests that therapeutic drug monitoring would 
be the best way to manage these patients, that dosing schedules should 
be altered or that other agents, such as ceftaroline, should be considered. 
The above notwithstanding, the recommended therapy for meningitis 
is ceftriaxone. Both AC and ROC performed equivalently in this study.
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